Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non-Current Assets: 2010-2025

Historic Other Non-Current Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $539,000.

  • Lineage Cell Therapeutics' Other Non-Current Assets fell 11.06% to $539,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $539,000, marking a year-over-year decrease of 11.06%. This contributed to the annual value of $614,000 for FY2024, which is 6.41% up from last year.
  • Lineage Cell Therapeutics' Other Non-Current Assets amounted to $539,000 in Q3 2025, which was up 5.48% from $511,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Other Non-Current Assets high stood at $639,000 for Q1 2022, and its period low was $504,000 during Q1 2025.
  • For the 3-year period, Lineage Cell Therapeutics' Other Non-Current Assets averaged around $574,545, with its median value being $588,000 (2023).
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Other Non-Current Assets grew by 9.78% in 2024, and later dropped by 15.44% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Non-Current Assets (Quarterly) stood at $630,000 in 2021, then declined by 0.48% to $627,000 in 2022, then declined by 7.97% to $577,000 in 2023, then increased by 6.41% to $614,000 in 2024, then decreased by 11.06% to $539,000 in 2025.
  • Its last three reported values are $539,000 in Q3 2025, $511,000 for Q2 2025, and $504,000 during Q1 2025.